KalVista (KALV) announced that its wholly-owned subsidiary, KalVista Pharmaceuticals, has granted Pendopharm, a division of Pharmascience, the exclusive rights to manage the regulatory approval process and commercialization of sebetralstat in Canada. Sebetralstat is an investigational, oral on-demand treatment for hereditary angioedema. Financial terms of the agreement are not being disclosed.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALV:
- Optimistic Buy Rating for KalVista Pharmaceuticals Amidst Positive FDA Interactions and Imminent Decision on Sebetralstat
- Stifel calls report of Makary pushing for KalVista CRL ‘highly surprising’
- KalVista selloff on Endpoints report unwarranted, says JonesResearch
- FDA Commissioner pushed to reject KalVista drug, Endpoints News says
- KalVista volatile after Endpoints report on FDA Commissioner objection